 Home > Active Ingredient News > Immunology News > 2021ACR: Allopurinol and benzbromarone in the treatment of cardiovascular risk in patients with gout

2021ACR: Allopurinol and benzbromarone in the treatment of cardiovascular risk in patients with gout

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

blue heart lily

bumex 2 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although many studies have explored the treatment of gout patients with uric acid lowering heart vascular risk impact, but few studies have focused on the "Compare allopurinol and benzbromarone impact on cardiovascular risk in patients with gout difference"

Heart blood vessels

Research methods

The researchers used the Korean Health Insurance Review and Evaluation Service (HIRA) database to find gout patients 18 years of age and older who had been treated with allopurinol or benzbromarone between 2009 and 2015

Included population: 257,097 people in the allopurinol group, 7868 people in the benzbromarone group (mean age 54.

Exclusion criteria: The investigator excluded patients who had received other uric acid-lowering drugs or dialysis treatment for 1 year before the target date (the date when the treatment began with allopurinol or benzbromarone).

Study endpoints: The primary endpoint of the study was the occurrence of the composite cardiovascular endpoints, including coronary artery revascularization, MI hospitalization, ischemic brain stroke and TIA (transient ischemic attack)

Stroke

Research result

The adjusted hazard ratio (aHR) of the composite CV endpoint between the two groups was 1.

Reference source:

Yeonghee Eun,et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.